Reshape Lifesciences Stock Revenue
| RSLS Stock | USD 5.75 0.20 3.60% |
ReShape Lifesciences fundamentals help investors to digest information that contributes to ReShape Lifesciences' financial success or failures. It also enables traders to predict the movement of ReShape Stock. The fundamental analysis module provides a way to measure ReShape Lifesciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ReShape Lifesciences stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 8.7 M | 5.4 M |
ReShape | Revenue |
ReShape Lifesciences Company Revenue Analysis
ReShape Lifesciences' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current ReShape Lifesciences Revenue | 8.68 M |
Most of ReShape Lifesciences' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ReShape Lifesciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of ReShape
Projected quarterly revenue analysis of ReShape Lifesciences provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of ReShape Lifesciences match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in ReShape Lifesciences' stock price.
ReShape Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for ReShape Lifesciences is extremely important. It helps to project a fair market value of ReShape Stock properly, considering its historical fundamentals such as Revenue. Since ReShape Lifesciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ReShape Lifesciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ReShape Lifesciences' interrelated accounts and indicators.
| 0.42 | 0.43 | -0.44 | 0.31 | 0.62 | ||
| 0.42 | 1.0 | -0.71 | 0.22 | 0.82 | ||
| 0.43 | 1.0 | -0.71 | 0.26 | 0.83 | ||
| -0.44 | -0.71 | -0.71 | -0.46 | -0.78 | ||
| 0.31 | 0.22 | 0.26 | -0.46 | 0.37 | ||
| 0.62 | 0.82 | 0.83 | -0.78 | 0.37 |
Click cells to compare fundamentals
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
ReShape Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, ReShape Lifesciences reported 8.68 M of revenue. This is 99.89% lower than that of the Health Care Equipment & Supplies sector and 99.66% lower than that of the Health Care industry. The revenue for all United States stocks is 99.91% higher than that of the company.
ReShape Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ReShape Lifesciences' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ReShape Lifesciences could also be used in its relative valuation, which is a method of valuing ReShape Lifesciences by comparing valuation metrics of similar companies.ReShape Lifesciences is currently under evaluation in revenue category among its peers.
ReShape Lifesciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of ReShape Lifesciences from analyzing ReShape Lifesciences' financial statements. These drivers represent accounts that assess ReShape Lifesciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ReShape Lifesciences' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 26.8M | 17.6M | 17.9M | 2.9M | 1.5M | 1.4M | |
| Enterprise Value | 24.7M | 15.1M | (4.6M) | (823.6K) | (2.7M) | (2.6M) |
ReShape Lifesciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ReShape Lifesciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ReShape Lifesciences' managers, analysts, and investors.Environmental | Governance | Social |
ReShape Lifesciences Institutional Holders
Institutional Holdings refers to the ownership stake in ReShape Lifesciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of ReShape Lifesciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ReShape Lifesciences' value.| Shares | Goldman Sachs Group Inc | 2024-06-30 | 0.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Millennium Management Llc | 2024-06-30 | 0.0 | Vanguard Group Inc | 2024-09-30 | 0.0 | Geode Capital Management, Llc | 2024-09-30 | 0.0 | Xtx Topco Ltd | 2024-09-30 | 0.0 | Two Sigma Securities, Llc | 2024-06-30 | 0.0 | Virtu Financial Llc | 2024-06-30 | 58.9 K | Ubs Group Ag | 2024-06-30 | 57.8 K | Blackrock Inc | 2024-06-30 | 34.1 K | Hrt Financial Llc | 2024-06-30 | 19.6 K |
ReShape Fundamentals
| Return On Equity | -1.85 | ||||
| Return On Asset | -0.63 | ||||
| Profit Margin | (1.12) % | ||||
| Operating Margin | (1.05) % | ||||
| Current Valuation | 3.4 M | ||||
| Shares Outstanding | 712.68 K | ||||
| Shares Owned By Insiders | 5.57 % | ||||
| Shares Owned By Institutions | 1.83 % | ||||
| Number Of Shares Shorted | 25.01 K | ||||
| Price To Book | 2.66 X | ||||
| Price To Sales | 0.51 X | ||||
| Revenue | 8.68 M | ||||
| Gross Profit | 6.8 M | ||||
| EBITDA | (14.48 M) | ||||
| Net Income | (11.39 M) | ||||
| Cash And Equivalents | 11.49 M | ||||
| Cash Per Share | 0.51 X | ||||
| Total Debt | 262 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 2.12 X | ||||
| Book Value Per Share | 16.48 X | ||||
| Cash Flow From Operations | (16.96 M) | ||||
| Short Ratio | 0.22 X | ||||
| Earnings Per Share | 76.20 X | ||||
| Price To Earnings To Growth | (12.12) X | ||||
| Target Price | 1.0 | ||||
| Number Of Employees | 29 | ||||
| Beta | 1.35 | ||||
| Market Capitalization | 3.64 M | ||||
| Total Asset | 10.66 M | ||||
| Retained Earnings | (635.57 M) | ||||
| Working Capital | 6.52 M | ||||
| Net Asset | 10.66 M |
About ReShape Lifesciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ReShape Lifesciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ReShape Lifesciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ReShape Lifesciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ReShape Stock Analysis
When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.